Insights Into the Advantageous Positioning for Europe in Pharmaceutical Cannabis
Read an interview from Pharmaceutical Technology Europe exploring how the European bio/pharma industry’s high regulatory standards and GMP requirements are set to position the region as a frontrunner for pharmaceutical grade manufacturing of cannabis-based medicines.
Our sister publication, Pharmaceutical Technology Europe, recently conducted an interview with Michael Sassano, CEO at SOMAÍ Pharmaceuticals, to learn more about the European market and how pharmaceutical applications will shape up in the future.
There are various cannabis or cannabinoid-based products used in pharmacotherapy in Europe, mainly for treating chronic pain, nausea, and vomiting caused by chemotherapy. However, currently only one cannabinoid-based pharmaceutical product has been approved by the European Medicines Agency (EMA) under the centralized procedure, allowing it to be marketed throughout the entire European Union.
Click here to read the full article from Pharmaceutical Technology Europe’s February 2023 issue: https://www.pharmtech.com/view/advantageous-positioning-for-europe-in-pharmaceutical-cannabis
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
